- Home
- TVTX vs FOLD Comparison
TVTX vs FOLD Comparison
Compare TVTX & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVTX | FOLD |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | TVTX | FOLD |
|---|---|---|
| Price | $33.94 | $9.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $37.21 | $30.29 |
| AVG Volume (30 Days) | 1.5M | ★ 4.4M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $435,826,000.00 | ★ $598,704,000.00 |
| Revenue This Year | $120.36 | $21.49 |
| Revenue Next Year | $37.33 | $18.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 114.22 | 21.28 |
| 52 Week Low | $12.91 | $5.51 |
| 52 Week High | $37.50 | $10.57 |
Technical Indicators
Market Signals| Indicator | TVTX | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 61.43 |
| Support Level | $34.00 | $9.73 |
| Resistance Level | $35.79 | $10.05 |
| Average True Range (ATR) | 1.43 | 0.35 |
| MACD | -0.47 | -0.04 |
| Stochastic Oscillator | 10.00 | 43.25 |
Price Performance
Historical ComparisonAbout TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.